Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

According to Bloomberg News, Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) is being eyed by Roche (RHHBY - Analyst Report). People familiar with the situation, who declined to be identified, commented that Roche is seeking funds to finance the deal. Alexion Pharma, with a market cap of around $20 billion, surged more than 12% in Friday trading on the Nasdaq following rumors of the potential sale.

However, according to Reuters, Alexion Pharma's expensive valuation could prevent the transaction from materializing. Based on 2013 earnings estimates, Alexion is trading at 42.9x compared to the S&P average of 15.6x.

Roche is aiming to diversify its product portfolio through this potential takeover. The Swiss drugmaker boasts of a strong oncology portfolio. The acquisition of Alexion Pharma, if it materializes, would give Roche access to Alexion Pharma’s sole marketed drug Soliris.

Soliris is available for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare genetic disorder. In Sep 2011, the US Food and Drug Administration (FDA) cleared Soliris for treating children and adults suffering from atypical hemolytic uremic syndrome, an ultra-rare genetic disorder.

In Nov 2011, a similar approval for the drug was granted in the EU. Soliris is being studied for additional indications. The drug recorded sales of $1.13 billion in 2012, up 45%.

Strong Soliris sales for the PNH indication have helped the company achieve profitability since the second quarter of 2008. Sales of the drug have been boosted further by its label expansion into the aHUS indication.

Apart from rumors regarding Alexion Pharma’s potential takeover, Onyx Pharmaceuticals, Inc. is another stock in the biopharma space which is in the news as an acquisition target.

Alexion Pharma currently carries a Zacks Rank #3 (Hold). Jazz Pharmaceuticals (JAZZ - Analyst Report) appears to be more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 33.49 +8.84%
VALEO SA SPO VLEEY 68.09 +4.22%
DIXIE GROUP DXYN 14.64 +4.13%
INTERNATIONA ICAGY 32.67 +3.39%
CANADIAN SOL CSIQ 26.01 +3.34%